Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2
Open Access
- 5 January 2015
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 22 (s1) , 46-73
Abstract
Summary: The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries, and the relative impact of two scenarios was considered: (i) increased treatment efficacy while holding the treated population constant and (ii) increased treatment efficacy and increased annual treated population. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. In most countries, the annual treated population had to increase several fold to achieve the largest reductions in HCV‐related morbidity and mortality. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. In most of the studied countries, the majority of patients were born between 1945 and 1985.Keywords
Funding Information
- Gilead Sciences
- Medtronic
- Merck
- Bayer
- Novartis
- Boehringer Ingelheim
- AbbVie
- Bristol-Myers Squibb
- Janssen
- Ministry of Health
- Research Organization ZonMW
- Roche
- MSD
This publication has 16 references indexed in Scilit:
- Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone surveyJournal of Viral Hepatitis, 2014
- Prevalence and trends of markers of hepatitis B virus, hepatitis C virus and human Immunodeficiency virus in Argentine blood donorsBMC Infectious Diseases, 2014
- The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigmJournal of Viral Hepatitis, 2014
- A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C–Associated Liver CirrhosisClinical Infectious Diseases, 2013
- Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirationsGeneral Hospital Psychiatry, 2013
- The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in U.S. Primary Care SettingsAnnals of Internal Medicine, 2012
- Determination of the burden of hepatitis C virus infection in IrelandEpidemiology and Infection, 2011
- Predictors of response of U.S. veterans to treatment for the hepatitis C virusHepatology, 2007
- High Deferral Rates and Poorer Treatment Outcomes for HCV Patients with Psychiatric and Substance Use ComorbiditiesDigestive Diseases and Sciences, 2007
- Barriers to the treatment of hepatitis CJournal of General Internal Medicine, 2005